Primary study · included by 1 review
Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study.
van der Wall 2021 · van der Wall Sake J, Lip Gregory Y H, Teutsch Christine, et al. · European journal of internal medicine · 2021
Included by
The review does not say which of its outcomes this study informs.
1 including review in total.